Novo Nordisk A/S (NVO) had something to celebrate Tuesday morning. U.S.-listed shares surged 7.36% in premarket trading after the FDA granted approval for an oral version of Wegovy, making it the first GLP-1 weight-loss pill to win regulatory clearance anywhere in the world.

A Pill That Could Change Everything

The FDA's Monday approval represents a genuine breakthrough in the weight-loss drug market. For patients tired of weekly injections, the oral alternative offers a more convenient option. Novo Nordisk announced that the 1.5-milligram starting dose will hit pharmacies and select telehealth providers by early January, with a price tag of $149 per month.

Here's where it gets interesting: patients paying out of pocket can also access the pill through President Donald Trump's direct-to-consumer platform, TrumpRx, following an agreement the company struck with the administration last month. That's the same $149 monthly rate.

Winning After a Rough Year

The timing couldn't be better for the Danish pharmaceutical company. It's been a bruising year filled with board conflicts, supply chain headaches, a bidding war with Pfizer (PFE), and plenty of criticism about its U.S. strategy. This approval gives Novo Nordisk a meaningful lead over American rival Eli Lilly (LLY) in the race to dominate the weight-loss drug market.

The company isn't resting on this win, either. Earlier this month, Novo Nordisk filed a New Drug Application with the FDA for CagriSema, a weekly combination obesity shot that pairs a long-acting amylin analogue with semaglutide, a GLP-1 receptor agonist. If approved, CagriSema would become the first injectable treatment combining both mechanisms, potentially strengthening the company's position even further.

But not everything is moving in Novo Nordisk's favor. In November, the U.S. Centers for Medicare & Medicaid Services announced negotiated prices for 15 high-cost medications, taking effect in 2027. Under the new pricing structure, semaglutide products including Wegovy, Ozempic, and Rybelsus will carry a monthly cost of $274, lower than current rates.

The stock has faced significant headwinds throughout the year. Disappointing results from the REDEFINE 2 phase 3 trial of CagriSema hit investor confidence hard. Making matters worse, the company has revised its 2025 sales growth guidance downward multiple times, adding to the pressure.

The Numbers Tell a Mixed Story

Market data places Novo Nordisk in the 53rd percentile for quality and the 30th percentile for value, suggesting average performance in both categories. The stock has dropped 45.04% year-to-date, though it managed a modest 0.02% gain on Monday to close at $88.33 before Tuesday's premarket surge.

For a company that dominated headlines with blockbuster weight-loss drugs just a year ago, this FDA approval might mark the beginning of a comeback story. Or at least a stabilization after twelve months of challenges. The oral pill addresses a real patient need, and being first to market with this formulation matters in a competitive landscape where Eli Lilly has been breathing down Novo's neck.